Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib in metastatic castrate-resistant prostate cancer
NCT01519414Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tivantinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started Jan 2012; status: completed.
02
Drugs
tivantinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01519414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01519414.